A target product profile (TPP) is a planning document that describes a drug in the format of its future label: indication, population, dosing, efficacy, safety, and presentation. It states what the product must achieve to be worth developing. Investors ask for it because it shows whether a team has defined what it is building, the evidence that will prove it, and the point at which it would stop.
What exactly is a target product profile?
FDA introduced the TPP in a March 2007 draft guidance titled "Target Product Profile: A Strategic Development Process Tool." The agency described it as a format for summarizing a development program in terms of labeling concepts, prepared voluntarily by the sponsor to focus discussions with review staff [1]. Sharing one does not bind the sponsor to that label.
That draft was never finalized. FDA lists it among withdrawn drug guidances, issued March 30, 2007 and withdrawn December 13, 2019 [2]. In my experience the withdrawal changed nothing in practice. Review divisions still understand a TPP instantly, NIH institutes publish templates built on it, and investors expect one.
The structure follows the prescribing information required by 21 CFR 201.57: indications and usage, dosage and administration, contraindications, warnings and precautions, adverse reactions, use in specific populations, clinical pharmacology, clinical studies, and how supplied [3]. Writing the TPP in that order forces a team to confront every label section it will eventually have to defend.
What goes into a TPP, and what do "minimum" and "target" mean?
The most important design choice is to give every attribute two values. The National Institute on Drug Abuse's TPP template organizes each label attribute into "Minimum Acceptable Results" and "Ideal Results" columns and calls the TPP a dynamic document that evolves with emerging data [4]. WHO's TPPs use the same logic, pairing optimal characteristics with minimal characteristics below which a product is unlikely to be useful [5].
The minimum column is the product still worth approving, paying for, and prescribing. The target column is the product that wins its market. Data below the minimum mean stop; data between the two mean viable but repositioned. The table shows how I lay this out for a hypothetical biologic in a relapsed hematologic malignancy.
| TPP dimension | Minimum acceptable | Target |
|---|---|---|
| Indication and line | Third-line, after two prior regimens | Second-line, plus a pediatric subpopulation |
| Efficacy | 30% overall response rate, single-arm study | 50% response rate with durable remissions |
| Safety | Toxicity no worse than standard of care | Outpatient dosing, no routine hospitalization |
| Dosing and presentation | Intravenous infusion every two weeks | Subcutaneous or once-monthly dosing |
| Differentiation | Activity in patients refractory to the standard | Mechanism that supports combination with the standard |
Many published TPPs skip this discipline. A 2024 systematic review of 138 peer-reviewed papers containing TPPs found that 57.8% stated only one threshold level of performance, and most did not describe how the profile was developed [6]. A single-threshold TPP reads as a wish list. It gives reviewers and investors nothing to test the data against.
How does a TPP drive go/no-go decisions and trial design?
Every row of the TPP implies a study. If the target claim is a durable remission, the Phase 1 expansion cohort needs a duration endpoint and enough follow-up to measure it. If the minimum safety claim is outpatient dosing, the protocol needs a monitoring plan to show it. I write the study column alongside each claim, so a claim with no feasible study is deleted early.
The TPP also sets the chemistry, manufacturing, and controls agenda. ICH Q8(R2), adopted by FDA in 2009, defines a quality target product profile as a prospective summary of the quality characteristics a drug product should achieve, considering route, dosage form, strength, and stability [7]. A clinical TPP calling for subcutaneous dosing therefore commits the program to a concentration and viscosity target years before the first patient.
On the first-in-class biologic I managed for a rare pediatric leukemia, the TPP also became the instrument for label expansion. I mapped the target biology onto larger adjacent disease populations and scored each candidate indication against the same rows: unmet need, efficacy bar, safety tolerance, and dosing fit. Indications that cleared the minimum in relevant nonclinical models moved the potential U.S. addressable market from roughly $200M per year toward the multi-billions.
How does FDA actually use a TPP?
FDA does not require a TPP and does not review one as a submission. It uses the document as an agenda. In a 2017 Federal Register notice on the draft guidance, FDA estimated about 20 sponsors submitting roughly 132 TPPs per year, at about 20 hours each [8].
A TPP earns its keep at formal meetings. FDA's 2026 final guidance on formal meetings sets scheduling goals of 60 calendar days for Type B and 75 for Type C meetings, and asks packages to describe substantive changes such as a new indication or population, with up to 10 final questions [9]. A current TPP makes each question traceable to a label claim.
Planning of this kind correlates with smoother reviews. FDA staff reported that approved drugs and biologics whose reviews mentioned a TPP had more efficient review times, and called the tool advantageous but underused [10], [11]. A 2023 WHO Bulletin article summarized the effect as roughly 10% faster approval [5]. Correlation is not cause: well-organized sponsors may simply write more TPPs.
Why do investors ask for a TPP?
The arithmetic of drug development makes a written target essential. A 2020 JAMA analysis of 63 therapeutics approved from 2009 to 2018 estimated a median capitalized research and development cost of about $1.1 billion per drug, including failures, after the authors' 2022 correction [12]. Across 2011 to 2020, only 7.9% of candidates entering Phase 1 reached approval, and Phase 2 was the largest hurdle, with 28.9% advancing [13].
An investor cannot change those odds, but can insist on knowing what success means before funding a round. The TPP answers in a form a diligence team can test row by row: does the minimum efficacy bar clear the standard of care, is the population large enough to justify the price, and has the team decided what data would make it stop?
Investors also read the TPP as a payer document. In a 2022 survey answered by 11 pharmaceutical companies, all 11 included the target population in their TPP, 91% addressed safety and magnitude of effect, and about half built in payer and health technology assessment perspectives from inception [14]. A reimbursement row shows the team has thought past approval to revenue.
What can a TPP not do?
A TPP is a hypothesis, not evidence. It can state a 50% response rate as the target, but only a trial can deliver one. Early TPPs are usually too optimistic, and I have revised every one I have written at least once. A dated change log showing which claims survived contact with data persuades an investor more than a pristine first draft.
A TPP also does not bind FDA, which may disagree with any claim in it [1]. The right use is to bring it to a pre-IND or end-of-Phase 2 meeting as the frame for specific questions, then update it the same week.
If you are building or rebuilding a TPP for a live program and want a second set of eyes to review, I can provide an informed outside perspective. Reach me at info@hamiltonatlas.com.
References
- U.S. Food and Drug Administration. Draft Guidance for Industry and Review Staff on Target Product Profile--A Strategic Development Process Tool; Availability. Federal Register 72 FR 15141, 2007.
- U.S. Food and Drug Administration. Withdrawn and Expired Guidances | Drugs. FDA, 2026.
- U.S. Government Publishing Office. 21 CFR 201.57 Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1). Code of Federal Regulations, 2024.
- National Institute on Drug Abuse. Target Product Profiles (TPPs) for Medical Product Development. National Institutes of Health, 2025.
- Charnaud SC, Moorthy V, Reeder J, Ross AL. WHO target product profiles to shape global research and development. Bulletin of the World Health Organization. 2023;101(5):326-330.
- Ibnidris A, Liaskos N, Eldem E, et al. Facilitating the use of the target product profile in academic research: a systematic review. Journal of Translational Medicine. 2024;22(1):693.
- U.S. Food and Drug Administration. Q8(R2) Pharmaceutical Development. FDA, 2009.
- U.S. Food and Drug Administration. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Draft Guidance for Industry and Review Staff on Target Product Profile--A Strategic Development Process Tool. Federal Register 82 FR 51849, 2017.
- U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. FDA, 2026.
- Breder CD, Du W, Tyndall A. What's the Regulatory Value of a Target Product Profile? Trends in Biotechnology. 2017;35(7):576-579.
- Tyndall A, Du W, Breder CD. The target product profile as a tool for regulatory communication: advantageous but underused. Nature Reviews Drug Discovery. 2017;16(3):156.
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853.
- Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011-2020. BIO, 2021.
- Wang T, McAuslane N, Goettsch WG, Leufkens HGM, De Bruin ML. Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile. Frontiers in Pharmacology. 2022;13:948161.